rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sven Ante Lundberg

Director

Company insider

Files Form 4 as: Director, Q32 Bio; President, CEO & PEO, Merus; Director, Vor Biopharma; Chief Scientific Officer, CRISPR Therapeutics AG.

Every Form 4 they filed

In numbers

Trades disclosed
79
Buys
5
Sells
0
Bought
$466K
Sold
$0
Companies
4
Companies where not an officer
2
First trade
24 Oct 2016
Last trade
12 Jun 2026
Last filed
21 Jul 2026

Companies traded

Where they are an officer
MerusDirector, Officer · last 12 Dec 20254 buys · 0 sells
CRSP CRISPR Therapeutics AGOfficer · Genomics & Gene Editing · last 24 Oct 20161 buy · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
QTTB Q32 BioDirector · Biotechnology · last 12 Jun 20260 buys · 0 sells
VOR Vor BiopharmaDirector · Biotechnology · last 22 May 20250 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 Jun 2026filed 21 Jul 2026QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—10,826 at $0.00filing
12 Jun 2026filed 21 Jul 2026QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—10,826 at $0.00filing
12 Jun 2026filed 16 Jun 2026QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—9,810 at $0.00filing
12 Jun 2026filed 16 Jun 2026QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A—9,810 at $0.00filing
15 Jan 2026filed 30 Jan 2026QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A$56K20,363 at $2.75filing
15 Jan 2026filed 30 Jan 2026QTTB Q32 Biooption or derivative · BiotechnologySEC FORM 4 Code A$56K20,363 at $2.75filing
12 Dec 2025filed 12 Dec 2025Merusoption or derivativeSEC FORM 4 Code D—312,620 at $0.00filing
12 Dec 2025filed 12 Dec 2025Merusoption or derivativeSEC FORM 4 Code D—351,628 at $0.00filing
12 Dec 2025filed 12 Dec 2025Merusoption or derivativeSEC FORM 4 Code D—300,000 at $0.00filing
12 Dec 2025filed 12 Dec 2025Merusoption or derivativeSEC FORM 4 Code D—360,000 at $0.00filing
12 Dec 2025filed 12 Dec 2025Merusoption or derivativeSEC FORM 4 Code D—380,000 at $0.00filing
12 Dec 2025filed 12 Dec 2025Merusoption or derivativeSEC FORM 4 Code D—295,000 at $0.00filing
12 Dec 2025filed 12 Dec 2025MerusSEC FORM 4 Code U$2.9M30,297 at $97.00filing
12 Dec 2025filed 12 Dec 2025MerusSEC FORM 4 Code U$1.6M16,372 at $97.00filing
12 Dec 2025filed 12 Dec 2025MerusSEC FORM 4 Code U$892K9,191 at $97.00filing
12 Dec 2025filed 12 Dec 2025MerusSEC FORM 4 Code U$892K9,191 at $97.00filing
12 Dec 2025filed 12 Dec 2025MerusSEC FORM 4 Code U$892K9,192 at $97.00filing
12 Dec 2025filed 12 Dec 2025MerusSEC FORM 4 Code U$892K9,192 at $97.00filing
25 Nov 2025filed 28 Nov 2025MerusSEC FORM 4 Code G—30,297 at $0.00filing
25 Nov 2025filed 28 Nov 2025MerusSEC FORM 4 Code G—30,297 at $0.00filing

Sectors

Health Care1
Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Andrew Jacob SilverChief Financial Officer · Chief Financial Officer at CRISPR Therapeutics AG, filing Form 4 there in the last year
Samarth KulkarniChief Executive Officer · Chief Executive Officer at CRISPR Therapeutics AG, filing Form 4 there in the last year
Simeon GeorgeDirector · Director at CRISPR Therapeutics AG, filing Form 4 there in the last year
James R. KasingerGeneral Counsel and Secretary · General Counsel and Secretary at CRISPR Therapeutics AG, filing Form 4 there in the last year
Ali BehbahaniDirector · Director at CRISPR Therapeutics AG, filing Form 4 there in the last year